The AKAP8L Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-mediated gene-disrupted cell pool targeting the human AKAP8L locus in HeLa cells. This product is supplied as a heterogeneous population of edited cells, providing a loss-of-function model for investigating AKAP8L-dependent processes. The polyclonal knockout format is generated via transient introduction of CRISPR components, resulting in a mixed genotype that can be used for pooled functional studies or further subcloning. As an advanced gene-editing product, this cell model enables researchers to interrogate the roles of AKAP8L in pre-mRNA splicing and nuclear envelope dynamics within a relevant human cellular background.
HeLa cells are derived from a human cervical adenocarcinoma and are positive for human papillomavirus type 18 (HPV-18). This epithelial cell line is a widely established model in cancer biology, particularly for studies of cervical cancer pathogenesis, viral oncogenesis, and cell cycle deregulation. The background of these cells offers a well-characterized platform in which AKAP8L functions can be probed, as the oncogenic environment potentially alters splicing and nuclear envelope processes. HeLa cells also provide robust growth characteristics and well-documented signaling networks, facilitating reproducible knockdown and knockout experiments.
AKAP8L encodes a nuclear A-kinase anchoring protein that tethers protein kinase A (PKA) regulatory subunits, concentrating cAMP/PKA signaling at subnuclear sites. It is regulated by phosphorylation from Aurora A and CDK1/cyclin B, which modulates its interactions with splicing factors such as SRp75 (SRSF4) and nuclear lamina components like Lamin A/C and Emerin. AKAP8L facilitates spliceosomal assembly on RNA polymerase II transcripts, coordinating pre-mRNA splicing of targets including Bcl-x and CD44. During mitotic exit, its interactions with LAP2??, Emerin, and BAF drive nuclear envelope reassembly, thereby linking splicing control with cell cycle progression.
In the context of HeLa cells, disrupting AKAP8L provides a powerful system to dissect how nuclear scaffolding and splicing factor organization influence cervical adenocarcinoma cell biology. Because HeLa cells harbor HPV-18 oncoproteins that interfere with cell cycle control and apoptosis, AKAP8L knockout can reveal dependencies on splicing and nuclear envelope integrity for oncogenic growth. This model is particularly relevant for studying cervical cancer and adenocarcinoma, as well as splicing-related disorders and nuclear envelopathies. The polyclonal knockout population may exhibit heterogeneous phenotypes, reflecting the spectrum of editing events and allowing assessment of gene essentiality in a cancer context.
Researchers can use this AKAP8L knockout cell pool in Western blotting, RT-qPCR for splicing isoforms, and immunofluorescence for nuclear envelope markers like Lamin A/C. Co-immunoprecipitation can test interactions with PKA subunits or lamin components, and phospho-kinase profiling can track signaling changes. Flow cytometry and proliferation assays link AKAP8L status to cell cycle and growth. This model supports studies of alternative splicing, nuclear envelope dynamics, cell cycle, and cancer target validation. For technical support, contact Ascent Research.
